BikleD. Nonclassic actions of vitamin D. J Clin Endocrinol Metab. 2009;94:26‐34.
2.
MenezesRJCheneyRTHusainA. Vitamin D receptor expression in normal, premalignant, and malignant human lung tissue. Cancer Epidemiol Biomarkers Prev. 2008;17:1104‐1110.
3.
ValdivielsoJM. The physiology of vitamin D receptor activation. Contrib Nephrol. 2009;163:206‐212.
4.
LichtensteinGRSandsBEPazianasM. Prevention and treatment of osteoporosis in inflammatory bowel disease. Inflamm Bowel Dis. 2006;12:797‐813.
5.
NobleCLMcCulloughJHoW. Low body mass not vitamin D receptor polymorphisms predict osteoporosis in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2008;27:588‐596.
6.
Rodriguez‐BoresLBarahona‐GarridoJYamamoto‐FurushoJK. Basic and clinical aspects of osteoporosis in inflammatory bowel disease. World J Gastroenterol. 2007;13:6156‐6165.
7.
SaponeNPellicanoRSimondiD. A 2008 panorama on osteoporosis and inflammatory bowel disease. Minerva Med. 2008;99:65‐71.
8.
SonnenbergAMcCartyDJJacobsenSJ. Geographic variation of inflammatory bowel disease within the United States. Gastroenterology. 1991;100:143‐149.
9.
MullinGEDobsA. Vitamin D and its role in cancer and immunity: a prescription for sunlight. Nutr Clin Pract. 2007;22:305‐322.
10.
NguyenHDBakshiAKBorumML. The frequency of osteoporosis screening in men with inflammatory bowel disease [published online ahead of print February 2, 2009]. Am J Mens Health.
11.
BakshiANguyenHBorumM. Vitamin D screening by gastroenterologists in patients with inflammatory bowel disease. Am J Gastroenterol. 2009;103:1451‐1459.
12.
CantornaMT. Vitamin D and its role in immunology: multiple sclerosis, and inflammatory bowel disease. Prog Biophys Mol Biol. 2006;92:60‐64.
13.
CantornaMTMahonBD. D‐hormone and the immune system. J Rheumatol Supp. 2005;76:11‐20.
14.
FroicuMZhuYCantornaMT. Vitamin D receptor is required to control gastrointestinal immunity in IL‐10 knockout mice. Immunology. 2006;117:310‐318.
15.
ZhuYMahonBDFroicuMCantornaMT. Calcium and 1 alpha, 25‐dihydroxyvitamin D3 target the TNF‐alpha pathway to suppress experimental inflammatory bowel disease. Eur J Immunol. 2005;35:217‐224.
16.
MullinGEPickett‐BlakelyOClarkeJO. Integrative medicine in gastrointestinal disease: evaluating the evidence. Expert Rev Gastroenterol Hepatol. 2008;2:261‐280.
